LFG
TVTX icon

Larson Financial Group’s Travere Therapeutics TVTX Stock Holding History

Larson Financial Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2K Buy
179
+12
+7% +$532 ﹤0.01% 2396
2026
Q1 		$4.96K Buy
167
+2
+1% +$60 ﹤0.01% 2616
2025
Q4 		$6.3K Buy
165
+26
+19% +$845 ﹤0.01% 2365
2025
Q3 		$3.32K Buy
+139
New +$2.61K ﹤0.01% 2510

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Larson Financial Group's TVTX Position: Q2 2026 in Review

Larson Financial Group increased its Travere Therapeutics (TVTX) stake by 7.2% in Q2 2026, buying an estimated $532 and bringing the position to 179 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2396.

Larson Financial Group first reported a position in TVTX in Q3 2025 and has held it in 4 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Larson Financial Group held 179 shares of Travere Therapeutics worth $10.2K as of Q2 2026.
  • Larson Financial Group bought 12 Travere Therapeutics shares in Q2 2026, an estimated $532.
  • Travere Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2396 holding.
  • Larson Financial Group first reported a position in Travere Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.